102.92
-0.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Halozyme Therapeutics
From its filings with the US Securities and Exchange Commission
Halozyme Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HALO. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $1.40bn and net income of $316.9m. At that date it held total assets of $2.53bn and shareholders' equity of $48.8m. By region, United States accounted for 58.9%, followed by Switzerland at 19.8% and Belgium at 15.6%.
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme, rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds. We are also developing partner products with Hypercon™ drug delivery technology (“Hypercon technology”) and developing the Surf Bio drug delivery technology to expand the breadth of our drug delivery technology portfolio. Hypercon technology is an innovative microparticle technology that has been demonstrated in non-clinical testing to enable hyperconcentration of drugs and biologics and reduce the injection volume for the same dosage, potentially expanding opportunities for at-home and health care provider administration. The Surf Bio hyperconcentration technology is being developed to create high antibody and biologic concentrations of up to 500 mg/mL, for delivery in a single auto-injector shot for at-home or in a health care provider’s office use.
Quoted from its 10-K, filed 17 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jan 2003
- Employees
- 423
- Website
- halozyme.com ↗
- Head office
- 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Jeffrey HendersonIndependent Chairman of the Board$544,817
- Dr. Helen TorleyPresident, Chief Executive Officer, Director, since 2014$12.7m
- Ms. Nicole LabrosseChief Financial Officer, Senior Vice President$4.2m
- Ms. Cortney CaudillChief Operating Officer, Senior Vice President
- Mr. Mark SnyderSenior Vice President, Chief Compliance Officer, General Counsel, Secretary$5.4m
- Ms. Bernadette ConnaughtonIndependent Director$470,037
- Ms. Barbara DuncanIndependent Director$485,257
- Dr. Mahesh KrishnanIndependent Director$437,510
- Ms. Moni MiyashitaIndependent Director$455,037
- Mr. Matthew PosardIndependent Director$475,037
- Ms. Tram BuiVice President - Investor Relations and Corporate Communications, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 99
- Social
- 79
- Governance
- 69
- Direct emissions (scope 1)
- 1,347.71 t
- Energy emissions (scope 2)
- 2,113.45 t
- Value chain emissions (scope 3)
- 30.46 t
- Women in the workforce
- 44%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Halozyme Therapeutics Inc has a robust and diverse product portfolio that includes a range of innovative and effective therapies. This allows the company to cater to various medical conditions and target a wide market segment.
- The company has a proven track record of developing and commercializing successful therapies. This track record enhances its reputation and credibility in the market, attracting investors and potential strategic partners.
Weaknesses
- Halozyme Therapeutics Inc heavily relies on partnerships with other pharmaceutical companies for research, development, and commercialization. This dependency exposes the company to risks associated with potential conflicts, delays, or failures in partnerships.
- The pharmaceutical industry is subject to strict regulatory guidelines and approvals. Halozyme Therapeutics Inc may face challenges in obtaining regulatory clearances for its therapies, which can lead to delays in product launches and revenue generation.
Opportunities
- The increasing prevalence of chronic diseases and the aging population create a growing demand for advanced therapies. Halozyme Therapeutics Inc can leverage this opportunity by developing and offering solutions that address unmet medical needs.
- The company can explore expansion into new geographic markets to tap into additional revenue streams. By targeting emerging markets or regions with limited competition, Halozyme Therapeutics Inc can gain a competitive advantage and strengthen its market position.
Threats
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Halozyme Therapeutics Inc faces the threat of competition from both established pharmaceutical companies and emerging biotech startups.
- Protecting intellectual property rights is crucial in the pharmaceutical industry. Halozyme Therapeutics Inc may face risks such as patent infringements or unauthorized use of its technologies, potentially impacting its market exclusivity and revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.